There is no generic or biosimilar version of Repatha (evolocumab) available in the United States as of 2025. Because Repatha is a biologic medication rather than a traditional small-molecule drug, it won’t get a conventional generic. Instead, it would eventually face competition from “biosimilars,” which are near-copies of biologic drugs. None have been approved yet.
Why Repatha Can’t Have a Traditional Generic
Repatha is a monoclonal antibody, a large, complex protein made from living cells. Traditional generics are chemically identical copies of simple pills, which are relatively straightforward to reproduce. Biologics like Repatha are far more complicated to manufacture, and no two production processes yield an identical molecule. That’s why the FDA created a separate approval pathway for biosimilars, which must demonstrate they are highly similar to the original biologic and produce no meaningful clinical differences.
This distinction matters for your wallet. Biosimilars typically cost 15% to 35% less than the original biologic, a smaller discount than the 80% to 90% drop you might see when a traditional drug goes generic.
Patent Protection and Timeline
One of Repatha’s key U.S. patents (No. 8,829,165) has an expiration date extended to August 2029. Until patent protections lapse or are successfully challenged, no biosimilar manufacturer can bring a competing product to market. No company has publicly announced an FDA application for a Repatha biosimilar, so even after patents expire, it would likely take additional years before a biosimilar reaches pharmacies.
What Repatha Costs Right Now
Repatha’s U.S. list price has historically been steep, in the range of $14,000 per year. In late 2025, Amgen launched AmgenNow, a direct-to-patient program offering Repatha at $239 per month, nearly 60% below the list price. The program is open to anyone, including uninsured patients, those on high-deductible plans, and people who prefer to pay cash.
If you have commercial insurance, a copay card from Amgen can reduce your out-of-pocket cost with no income requirement. Uninsured or underinsured patients may also qualify for free Repatha through the Safety Net Foundation. These programs exist precisely because there’s no biosimilar competition to drive prices down naturally.
How Repatha Works
Your liver clears LDL (“bad”) cholesterol from the bloodstream using surface receptors that grab LDL particles and pull them in. A protein called PCSK9 normally breaks down those receptors after each use, limiting how much cholesterol your liver can remove. Repatha blocks PCSK9, so the receptors survive longer and recycle back to the liver’s surface. More receptors means more LDL gets pulled out of circulation. The result is a 32% to 71% reduction in LDL cholesterol, depending on the dose and the patient’s underlying condition.
What Repatha Is Approved to Treat
The FDA has approved Repatha for several overlapping uses:
- Cardiovascular risk reduction in adults with established heart disease, to lower the chance of heart attack, stroke, and procedures to reopen blocked arteries
- High LDL cholesterol in adults with primary hyperlipidemia, including inherited forms, when diet and other medications aren’t enough
- High LDL cholesterol in children 10 and older with inherited familial hypercholesterolemia
- Homozygous familial hypercholesterolemia in adults and children 10 and older, alongside other cholesterol-lowering treatments
Praluent: The Closest Alternative
The only other PCSK9 inhibitor on the market is Praluent (alirocumab), which works through the same mechanism. Praluent reduces LDL by 8% to 67%, compared to Repatha’s 32% to 71%, though direct comparisons depend on the dose and patient population studied. Praluent is injected every two weeks. Repatha offers more dosing flexibility: you can inject every two weeks or use a monthly option.
Pricing for both drugs is similar, and neither has a biosimilar competitor. If your insurance covers one but not the other, or if you tolerate one better, switching between them is a reasonable conversation to have with your doctor.
How Repatha Is Taken
Repatha is a self-administered injection, not a pill. There are two main delivery options. The SureClick autoinjector is a pen-like device that delivers 140 mg in about 15 seconds. For the higher 420 mg monthly dose, you’d give yourself three separate autoinjector shots within a 30-minute window. Alternatively, the Pushtronex on-body infuser is a small device you stick to your skin that delivers the full 420 mg dose over about 5 minutes in a single session. Both are designed for home use after initial training.
For most people searching for a generic, cost is the real concern. Until biosimilar competition arrives, Amgen’s direct pricing program and copay assistance are the most practical ways to bring the price down.